Identification and design of a novel series of MGAT2 inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 23, Issue 9, 2013, Pages 2721-2726

  Barlind, Jonas G ^a   Buckett, Linda K ^b   Crosby, Sharon G ^b   Davidsson, Öjvind ^a   Emtenäs, Hans ^a   Ertan, Anne ^c   Jurva, Ulrik ^a   Lemurell, Malin ^a   Gutierrez, Pablo Morentin ^b   Nilsson, Karolina ^a   O'Mahony, Gavin ^a   Petersson, Annika U ^a   Redzic, Alma ^a   Wågberg, Fredrik ^a   Yuan, Zhong Qing ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

^c STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

Dioxotetrahydrobenzodiazepine; Metabolic syndrome; MGAT; Monoacylglycerol acyltransferase; Oral lipid tolerance test

Indexed keywords

ACYLGLYCEROL PALMITOYLTRANSFERASE; ACYLTRANSFERASE INHIBITOR; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG IDENTIFICATION; FAT TOLERANCE TEST; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PARAMETERS; REACTION OPTIMIZATION; STRUCTURE ACTIVITY RELATION; TRIACYLGLYCEROL BLOOD LEVEL;

ACYLTRANSFERASES; ADMINISTRATION, ORAL; ANIMALS; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; DRUG DESIGN; ENZYME INHIBITORS; HALF-LIFE; HUMANS; MICE; NANOSTRUCTURES; POVIDONE; STRUCTURE-ACTIVITY RELATIONSHIP; TRIGLYCERIDES;

EID: 84876120803     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2013.02.084     Document Type: Article

References (14)

1. C.-L.E. Yen, and R.V. Farese Jr. J. Biol. Chem. 278 2003 18532
2. R.M. Bell, and R.A. Coleman Annu. Rev. Biochem. 49 1980 459
3. C.-L.E. Yen, M.-L. Cheong, C. Grueter, P. Zhou, J. Moriwaki, J.S. Wong, B. Hubbard, S. Mamour, and R.V. Farese Jr. Nat. Med. 15 2009 442
4. D.W. Nelson, Y. Gao, N.M. Spencer, T. Banh, and C.-L.E. Yen J. Lipid Res. 52 2011 1723
5. Previously disclosed structurally distinct MGAT inhibitors. Patents: WO 2008038768 (A1), WO 2010095767 (A1), WO 2012091010 (A1) and WO 2012124744 (A1).
6. The X-ray coordinates have been deposited to the Cambridge Crystallographic Data Centre and allocated the deposition number CCDC 917232.
7. S.W. Gordon-Wylie, E. Teplin, J.C. Morris, M.I. Trombley, S.M. McCarthy, W.M. Cleaver, and G.R. Clark Cryst. Growth Des. 4 2004 789
8. T. Geerts, and Y. Van der Heyden Comb. Chem. High Throughput Screening 14 2011 339
9. R.A. Thompson, E.M. Isin, Y. Li, R. Weaver, L. Weidolf, I. Wilson, A. Claesson, K. Page, H. Dolgos, and G.J. Kenna Chem. Biol. Interact. 192 2011 65
10. H. Zhang, C.D. Davis, M.W. Sinz, and A.D. Rodrigues Expert Opin. Drug Metab. Toxicol. 2007 667
11. A. Corsini, and R. Ceska Curr. Med. Res. Opin. 27 2011 1551
12. Z.Z. Brown, and C.E. Schafmeister J. Am. Chem. Soc. 130 2008 14382
13. J.G. Barlind, U. Bauer, A.M. Birch, S. Birtles, L.K. Buckett, R.J. Butlin, J.W. Eriksson, C.D. Hammond, R. Hovland, P. Johannesson, M.J. Johansson, P.D. Kemmitt, B.T. Lindmark, P. Morentin Gutierrez, T. Noeske, A. Nordin, C. O'Donnell, A.U. Petersson, A. Redzic, A.V. Turnbull, and J. Vinblad J. Med. Chem. 55 2012 10610
14. J. Cao, J. Lockwood, P. Burn, and Y. Shi J. Biol. Chem. 278 2003 13860